Skip to main content Skip to main navigation menu Skip to site footer

Melatonin, an adjuvant for neonatal sepsis: a systematic review and meta-analysis

  • Dwi Hidayah ,
  • Harsono Salimo ,
  • Tunjung Wibowo ,
  • Brian Wasita ,
  • Vitri Widyaningsih ,
  • Hartono Hartono ,
  • Soetrisno Soetrisno ,

Abstract

Link of Video Abstract: https://youtu.be/QMfynOrGWxM

 

Introduction: Neonatal sepsis remains a serious health problem in some countries, especially in developing countries, like Indonesia. The standard treatment for sepsis is the administration of antibiotics. Melatonin, a hormone produced by the pineal gland, has beneficial effects in fighting free radicals, antioxidants, anti-inflammatory, and anti-apoptotic effects. However, in newborns, melatonin is minimally detectable. Adjuvant therapy is required for the deterrence and neonatal sepsis therapy. This study aims to systematically review and perform a meta-analysis of melatonin as an adjunctive therapy in treating neonatal sepsis with the addition of the most recent articles.

Methods: Databases of electronics used such as PubMed, Embase, and the Cochrane Central Controlled Trials Register were searched systematically in October 2022 for clinical trials reporting the efficacy of melatonin as adjunctive therapy for neonatal sepsis. We compared treatment responses between groups using serum C-reactive protein (CRP) levels as an endpoint biomarker. Data analysis was performed to appraise the quality of enrolled studies using a comprehensive meta-analysis Revman 5.4 and bias tool risk of the Cochrane Collaboration.

Results: Four trials with a total of 175 subjects were listed in the systematic review and meta-analysis. Pooled analysis showed a statistically significant mean difference in serum CRP level (mg/L) between groups 24 hours after adjuvant melatonin therapy (-1.63 mg/L; 95% CI: -3.20 to -0.054; P=0.043).

Conclusion: Melatonin as an adjunctive therapy significantly lowers CRP levels. Larger, sample size studies are necessary to establish clear clinical benefits of this treatment.

References

  1. Esposito S, Zampiero A, Pugni L, Tabano S, Pelucchi C, Ghirardi B, et al. Genetic polymorphisms and sepsis in premature neonates. PLoS One. 2014;9(7):e101248–e101248. Available from: https://pubmed.ncbi.nlm.nih.gov/25000179
  2. WHO. WHO Sepsis Technical Expert Meeting. 2018.
  3. Esposito S, Principi N. Adjunctive therapy to treat neonatal sepsis. Vol. 13, Expert Review of Clinical Pharmacology. Taylor and Francis Ltd; 2020. p. 65–73.
  4. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011/07/23. 2011;159(5):720–5. Available from: https://pubmed.ncbi.nlm.nih.gov/21784435
  5. Marseglia L, D’Angelo G, Manti S, Aversa S, Arrigo T, Reiter RJ, et al. Analgesic, anxiolytic and anaesthetic effects of melatonin: new potential uses in pediatrics. Int J Mol Sci. 2015;16(1):1209–20. Available from: https://pubmed.ncbi.nlm.nih.gov/25569095
  6. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. Journal of Pineal Research. Blackwell Publishing Ltd; 2016. p. 253–78.
  7. Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, et al. Extrapineal melatonin: Sources, regulation, and potential functions. Vol. 71, Cellular and Molecular Life Sciences. Birkhauser Verlag AG; 2014. p. 2997–3025.
  8. Gitto E, Marseglia L, Manti S, D’Angelo G, Barberi I, Salpietro C, et al. Protective role of melatonin in neonatal diseases. Oxid Med Cell Longev. 2013/11/19. 2013;2013:980374. Available from: https://pubmed.ncbi.nlm.nih.gov/24349616
  9. D’Angelo G, Chimenz R, Reiter RJ, Gitto E. Use of Melatonin in Oxidative Stress Related Neonatal Diseases. Antioxidants (Basel). 2020;9(6):477. Available from: https://pubmed.ncbi.nlm.nih.gov/32498356
  10. Gitto E, Pellegrino S, Gitto P, Barberi I, Reiter RJ. Oxidative stress of the newborn in the pre‐ and postnatal period and the clinical utility of melatonin. J Pineal Res. 2009;46(2):128–39. Available from: http://dx.doi.org/10.1111/j.1600-079x.2008.00649.x
  11. Henderson R, Kim S, Lee E. Use of melatonin as adjunctive therapy in neonatal sepsis: A systematic review and meta-analysis. Complement Ther Med. 2018;39:131–6. Available from: http://dx.doi.org/10.1016/j.ctim.2018.06.002
  12. El-Gendy FM, El-Hawy MA, Hassan MG. Beneficial effect of melatonin in the treatment of neonatal sepsis. The Journal of Maternal-Fetal & Neonatal Medicine. 2017;31(17):2299–303. Available from: http://dx.doi.org/10.1080/14767058.2017.1342794
  13. El Frargy M, El-sharkawy HM, Attia GF. Use of melatonin as an adjuvant therapy in neonatal sepsis. J Neonatal Perinatal Med. 2015;8(3):227–32. Available from: http://dx.doi.org/10.3233/npm-15814072
  14. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of Melatonin Treatment in Septic Newborns. Pediatr Res. 2001;50(6):756–60. Available from: http://dx.doi.org/10.1203/00006450-200112000-00021
  15. El-Kabbany ZA, El-Farghali OG, Khafagy SM, Shaaban HA, Osman HHA, Metwally MH. Melatonin as an adjuvant therapy in preterm infants with neonatal sepsis, randomized trial. Egyptian Pediatric Association Gazette. 2020;68(1). Available from: http://dx.doi.org/10.1186/s43054-019-0013-7
  16. Kosim M, Yunanto A, Dewi R. Buku Ajar Neonatologi Edisi Pertama. 2014.
  17. Galano A, Tan D-X, Reiter RJ. Melatonin: A Versatile Protector against Oxidative DNA Damage. Molecules. 2018;23(3):530. Available from: https://pubmed.ncbi.nlm.nih.gov/29495460
  18. Gitto E, Aversa S, Salpietro CD, Barberi I, Arrigo T, Trimarchi G, et al. Pain in neonatal intensive care: Role of melatonin as an analgesic antioxidant. J Pineal Res. 2012;52(3):291–5.
  19. del Valle Bessone C, Fajreldines HD, de Barboza GED, Tolosa de Talamoni NG, Allemandi DA, Carpentieri AR, et al. Protective role of melatonin on retinal ganglionar cell: In vitro an in vivo evidences. Life Sci. 2019;218:233–40.
  20. Fulia F, Gitto E, Cuzzocrea S, Reiter RJ, Dugo L, Gitto P, et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001;31:343–9.
  21. Posadzki PP, Bajpai R, Kyaw BM, Roberts NJ, Brzezinski A, Christopoulos GI, et al. Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action. BMC Med. 2018;16(1):18. Available from: https://pubmed.ncbi.nlm.nih.gov/29397794
  22. Gitto E, Reiter RJ, Cordaro SP, La Rosa M, Chiurazzi P, Trimarchi G, et al. Oxidative and Inflammatory Parameters in Respiratory Distress Syndrome of Preterm Newborns: Beneficial Effects of Melatonin. Am J Perinatol. 2004;21(4):209–16. Available from: http://dx.doi.org/10.1055/s-2004-828610
  23. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Vol. 2, Signal Transduction and Targeted Therapy. Springer Nature; 2017.
  24. Poggi C, Dani C. Sepsis and Oxidative Stress in the Newborn: From Pathogenesis to Novel Therapeutic Targets. Oxid Med Cell Longev. 2018;2018:9390140. Available from: https://pubmed.ncbi.nlm.nih.gov/30174784
  25. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012/01/13. 2012;5(1):9–19. Available from: https://pubmed.ncbi.nlm.nih.gov/23268465

How to Cite

Hidayah, D., Harsono Salimo, Tunjung Wibowo, Brian Wasita, Vitri Widyaningsih, Hartono, H., & Soetrisno Soetrisno. (2023). Melatonin, an adjuvant for neonatal sepsis: a systematic review and meta-analysis. Bali Medical Journal, 13(1), 101–105. https://doi.org/10.15562/bmj.v13i1.4681

HTML
2

Total
1

Share

Search Panel